Revance Therapeutics, Probability of Future Stock Price Finishing Under 5.9
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Revance |
Revance Therapeutics, Target Price Odds to finish below 5.9
The tendency of Revance Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 5.90 after 90 days |
| 3.65 | 90 days | 5.90 | close to 99 |
Based on a normal probability distribution, the odds of Revance Therapeutics, to stay under $ 5.90 after 90 days from now is close to 99 (This Revance Therapeutics, probability density function shows the probability of Revance Stock to fall within a particular range of prices over 90 days) . Probability of Revance Therapeutics, price to stay between its current price of $ 3.65 and $ 5.90 at the end of the 90-day period is about 53.46 .
Given the investment horizon of 90 days Revance Therapeutics, has a beta of -1.09 indicating Additionally Revance Therapeutics, has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Revance Therapeutics, Price Density |
| Price |
Predictive Modules for Revance Therapeutics,
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Revance Therapeutics,. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Revance Therapeutics, Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Revance Therapeutics, is not an exception. The market had few large corrections towards the Revance Therapeutics,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Revance Therapeutics,, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Revance Therapeutics, within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.57 | |
β | Beta against Dow Jones | -1.09 | |
σ | Overall volatility | 0.76 | |
Ir | Information ratio | -0.06 |
Revance Therapeutics, Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Revance Therapeutics, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Revance Therapeutics, can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Revance Therapeutics, is not yet fully synchronised with the market data | |
| Revance Therapeutics, appears to be risky and price may revert if volatility continues | |
| Revance Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 234.04 M. Net Loss for the year was (323.99 M) with profit before overhead, payroll, taxes, and interest of 103.69 M. | |
| Revance Therapeutics, currently holds about 233.82 M in cash with (216.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.2. | |
| Over 87.0% of the company shares are owned by institutional investors |
Revance Therapeutics, Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Revance Stock often depends not only on the future outlook of the current and potential Revance Therapeutics,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Revance Therapeutics,'s indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 84.6 M | |
| Cash And Short Term Investments | 253.9 M |
Revance Therapeutics, Technical Analysis
Revance Therapeutics,'s future price can be derived by breaking down and analyzing its technical indicators over time. Revance Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Revance Therapeutics,. In general, you should focus on analyzing Revance Stock price patterns and their correlations with different microeconomic environments and drivers.
Revance Therapeutics, Predictive Forecast Models
Revance Therapeutics,'s time-series forecasting models is one of many Revance Therapeutics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Revance Therapeutics,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Revance Therapeutics,
Checking the ongoing alerts about Revance Therapeutics, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Revance Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Revance Therapeutics, is not yet fully synchronised with the market data | |
| Revance Therapeutics, appears to be risky and price may revert if volatility continues | |
| Revance Therapeutics, has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 234.04 M. Net Loss for the year was (323.99 M) with profit before overhead, payroll, taxes, and interest of 103.69 M. | |
| Revance Therapeutics, currently holds about 233.82 M in cash with (216.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.2. | |
| Over 87.0% of the company shares are owned by institutional investors |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |